S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Haemonetics Co. stock logo
HAE
Haemonetics
$81.24
-2.7%
$78.97
$70.74
$95.26
$4.13B0.36455,213 shs845,073 shs
ICU Medical, Inc. stock logo
ICUI
ICU Medical
$95.77
-1.2%
$102.30
$78.28
$212.43
$2.33B0.69257,978 shs181,916 shs
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$72.03
+1.5%
$75.08
$62.58
$85.62
$4.18B0.89500,687 shs533,932 shs
Inari Medical, Inc. stock logo
NARI
Inari Medical
$38.59
-0.1%
$46.89
$37.92
$71.85
$2.24B0.841.13 million shs802,173 shs
Nevro Corp. stock logo
NVRO
Nevro
$12.07
-2.0%
$14.43
$12.05
$38.59
$442.73M0.89475,425 shs385,669 shs
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Haemonetics Co. stock logo
HAE
Haemonetics
-1.63%-3.50%+7.78%-0.51%-2.30%
ICU Medical, Inc. stock logo
ICUI
ICU Medical
+1.06%-3.82%-2.13%+2.69%-45.24%
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
-0.73%-3.51%-2.89%-10.14%-8.53%
Inari Medical, Inc. stock logo
NARI
Inari Medical
-0.16%-6.94%-14.61%-32.79%-41.02%
Nevro Corp. stock logo
NVRO
Nevro
+0.24%-6.10%-10.98%-33.80%-68.67%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Haemonetics Co. stock logo
HAE
Haemonetics
4.4946 of 5 stars
3.34.00.04.32.41.71.9
ICU Medical, Inc. stock logo
ICUI
ICU Medical
4.3651 of 5 stars
3.53.00.03.91.32.51.9
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
4.9458 of 5 stars
4.44.00.03.82.82.52.5
Inari Medical, Inc. stock logo
NARI
Inari Medical
2.0916 of 5 stars
3.32.00.00.01.83.30.6
Nevro Corp. stock logo
NVRO
Nevro
1.7663 of 5 stars
4.01.00.00.01.51.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Haemonetics Co. stock logo
HAE
Haemonetics
2.50
Moderate Buy$104.6728.84% Upside
ICU Medical, Inc. stock logo
ICUI
ICU Medical
3.00
Buy$123.0028.43% Upside
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
2.89
Moderate Buy$92.5028.42% Upside
Inari Medical, Inc. stock logo
NARI
Inari Medical
2.67
Moderate Buy$73.7191.02% Upside
Nevro Corp. stock logo
NVRO
Nevro
2.00
Hold$21.2375.90% Upside

Current Analyst Ratings

Latest ICUI, NARI, NVRO, MMSI, and HAE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$98.00
4/15/2024
Nevro Corp. stock logo
NVRO
Nevro
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$18.00 ➝ $16.00
4/12/2024
Haemonetics Co. stock logo
HAE
Haemonetics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$105.00
4/12/2024
Inari Medical, Inc. stock logo
NARI
Inari Medical
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
4/11/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$88.00
4/11/2024
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
CL King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$88.00
4/11/2024
Nevro Corp. stock logo
NVRO
Nevro
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$20.00 ➝ $16.00
4/8/2024
Nevro Corp. stock logo
NVRO
Nevro
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $14.00
4/3/2024
Nevro Corp. stock logo
NVRO
Nevro
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$18.00 ➝ $16.00
3/22/2024
Inari Medical, Inc. stock logo
NARI
Inari Medical
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$61.00 ➝ $52.00
3/6/2024
Inari Medical, Inc. stock logo
NARI
Inari Medical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Haemonetics Co. stock logo
HAE
Haemonetics
$1.17B3.53$4.76 per share17.06$16.22 per share5.01
ICU Medical, Inc. stock logo
ICUI
ICU Medical
$2.26B1.03$15.30 per share6.26$87.96 per share1.09
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$1.26B3.33$4.86 per share14.82$20.81 per share3.46
Inari Medical, Inc. stock logo
NARI
Inari Medical
$493.63M4.53$0.09 per share438.90$8.07 per share4.78
Nevro Corp. stock logo
NVRO
Nevro
$425.17M1.04N/AN/A$8.10 per share1.49

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Haemonetics Co. stock logo
HAE
Haemonetics
$115.40M$2.4633.0219.252.019.97%22.37%9.71%5/9/2024 (Confirmed)
ICU Medical, Inc. stock logo
ICUI
ICU Medical
-$29.66M-$1.23N/A17.80N/A-1.31%6.35%3.03%5/13/2024 (Estimated)
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$94.41M$1.6244.4619.681.997.51%14.63%9.19%4/30/2024 (Confirmed)
Inari Medical, Inc. stock logo
NARI
Inari Medical
-$1.64M-$0.03N/A104.30N/A-0.33%1.23%0.97%4/30/2024 (Confirmed)
Nevro Corp. stock logo
NVRO
Nevro
-$92.21M-$2.57N/AN/AN/A-21.69%-30.22%-15.17%5/7/2024 (Confirmed)

Latest ICUI, NARI, NVRO, MMSI, and HAE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Haemonetics Co. stock logo
HAE
Haemonetics
$0.88N/A-$0.88N/AN/AN/A  
5/7/2024N/A
Nevro Corp. stock logo
NVRO
Nevro
-$1.02N/A+$1.02N/AN/AN/A  
4/30/2024N/A
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$0.70N/A-$0.70N/AN/AN/A  
4/30/2024N/A
Inari Medical, Inc. stock logo
NARI
Inari Medical
-$0.16N/A+$0.16N/AN/AN/A  
2/28/2024Q4 2023
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
$0.77$0.81+$0.04$1.15$320.66 million$324.52 million    
2/28/202412/31/2023
Inari Medical, Inc. stock logo
NARI
Inari Medical
$0.01-$0.08-$0.09$0.18$131.82 million$132.10 million    
2/27/2024Q4 2023
ICU Medical, Inc. stock logo
ICUI
ICU Medical
$0.85$1.24+$0.39$3.19$564.77 million$587.86 million
2/21/2024Q4 2023
Nevro Corp. stock logo
NVRO
Nevro
-$0.50-$0.15+$0.35-$0.05$115.93 million$116.18 million
2/8/202412/31/2023
Haemonetics Co. stock logo
HAE
Haemonetics
$0.94$1.04+$0.10$1.47$320.84 million$336.20 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Haemonetics Co. stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
ICU Medical, Inc. stock logo
ICUI
ICU Medical
N/AN/AN/AN/AN/A
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
N/AN/AN/AN/AN/A
Inari Medical, Inc. stock logo
NARI
Inari Medical
N/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Haemonetics Co. stock logo
HAE
Haemonetics
0.91
2.92
1.76
ICU Medical, Inc. stock logo
ICUI
ICU Medical
0.74
2.53
1.06
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
0.68
5.45
3.95
Inari Medical, Inc. stock logo
NARI
Inari Medical
N/A
3.09
2.52
Nevro Corp. stock logo
NVRO
Nevro
0.72
6.37
4.94

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Haemonetics Co. stock logo
HAE
Haemonetics
99.67%
ICU Medical, Inc. stock logo
ICUI
ICU Medical
96.10%
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
99.66%
Inari Medical, Inc. stock logo
NARI
Inari Medical
90.98%
Nevro Corp. stock logo
NVRO
Nevro
95.52%

Insider Ownership

CompanyInsider Ownership
Haemonetics Co. stock logo
HAE
Haemonetics
1.79%
ICU Medical, Inc. stock logo
ICUI
ICU Medical
6.70%
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
3.70%
Inari Medical, Inc. stock logo
NARI
Inari Medical
10.60%
Nevro Corp. stock logo
NVRO
Nevro
3.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Haemonetics Co. stock logo
HAE
Haemonetics
3,03450.79 million49.88 millionOptionable
ICU Medical, Inc. stock logo
ICUI
ICU Medical
14,00024.37 million22.73 millionOptionable
Merit Medical Systems, Inc. stock logo
MMSI
Merit Medical Systems
6,95058.07 million55.92 millionOptionable
Inari Medical, Inc. stock logo
NARI
Inari Medical
1,30057.96 million51.82 millionOptionable
Nevro Corp. stock logo
NVRO
Nevro
1,21536.68 million35.58 millionOptionable

ICUI, NARI, NVRO, MMSI, and HAE Headlines

SourceHeadline
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
finance.yahoo.com - April 17 at 10:38 AM
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
prnewswire.com - April 17 at 8:30 AM
Nevro (NYSE:NVRO) Given New $16.00 Price Target at Royal Bank of CanadaNevro (NYSE:NVRO) Given New $16.00 Price Target at Royal Bank of Canada
americanbankingnews.com - April 16 at 3:44 AM
Nevro (NYSE:NVRO) Price Target Lowered to $16.00 at Royal Bank of CanadaNevro (NYSE:NVRO) Price Target Lowered to $16.00 at Royal Bank of Canada
marketbeat.com - April 15 at 3:31 PM
Mizuho Lowers Nevro (NYSE:NVRO) Price Target to $16.00Mizuho Lowers Nevro (NYSE:NVRO) Price Target to $16.00
americanbankingnews.com - April 13 at 5:32 AM
Nevro Corp. (NYSE:NVRO) Receives Consensus Rating of "Hold" from AnalystsNevro Corp. (NYSE:NVRO) Receives Consensus Rating of "Hold" from Analysts
americanbankingnews.com - April 12 at 2:34 AM
Nevro Corp. (NYSE:NVRO) Given Average Rating of "Hold" by AnalystsNevro Corp. (NYSE:NVRO) Given Average Rating of "Hold" by Analysts
marketbeat.com - April 12 at 2:33 AM
Mizuho Cuts Nevro (NYSE:NVRO) Price Target to $16.00Mizuho Cuts Nevro (NYSE:NVRO) Price Target to $16.00
marketbeat.com - April 11 at 8:25 AM
Nevro (NYSE:NVRO) Trading Up 5.5%Nevro (NYSE:NVRO) Trading Up 5.5%
marketbeat.com - April 9 at 12:12 PM
Nevro (NYSE:NVRO) PT Lowered to $14.00 at Wells Fargo & CompanyNevro (NYSE:NVRO) PT Lowered to $14.00 at Wells Fargo & Company
americanbankingnews.com - April 9 at 4:56 AM
Assenagon Asset Management S.A. Lowers Stock Holdings in Nevro Corp. (NYSE:NVRO)Assenagon Asset Management S.A. Lowers Stock Holdings in Nevro Corp. (NYSE:NVRO)
marketbeat.com - April 5 at 4:35 AM
Where Nevro Stands With AnalystsWhere Nevro Stands With Analysts
benzinga.com - April 3 at 1:52 PM
Citigroup Trims Nevro (NYSE:NVRO) Target Price to $16.00Citigroup Trims Nevro (NYSE:NVRO) Target Price to $16.00
marketbeat.com - April 3 at 12:14 PM
Nevro (NYSE:NVRO) Stock Price Down 4.8%Nevro (NYSE:NVRO) Stock Price Down 4.8%
marketbeat.com - April 1 at 2:58 PM
EnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology CommercializationEnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology Commercialization
finanznachrichten.de - March 25 at 4:30 PM
Heres Why You Should Retain Nevro (NVRO) Stock for NowHere's Why You Should Retain Nevro (NVRO) Stock for Now
zacks.com - March 21 at 1:36 PM
NVRO Mar 2024 20.000 putNVRO Mar 2024 20.000 put
finance.yahoo.com - March 11 at 12:27 AM
Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral ScrewNevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw
zacks.com - February 29 at 8:31 AM
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral ScrewNevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
prnewswire.com - February 28 at 4:10 PM
Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)
markets.businessinsider.com - February 27 at 1:07 AM
Nevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market UncertaintyNevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market Uncertainty
markets.businessinsider.com - February 26 at 7:38 AM
Nevro just downgraded at Oppenheimer, heres whyNevro just downgraded at Oppenheimer, here's why
realmoney.thestreet.com - February 23 at 2:42 AM
Nevro Corp.: Nevro Reports Fourth-Quarter and Full-Year 2023 Financial ResultsNevro Corp.: Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
finanznachrichten.de - February 22 at 9:41 PM
Why Nevro Stock Lagged the Market on ThursdayWhy Nevro Stock Lagged the Market on Thursday
fool.com - February 22 at 6:21 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Haemonetics logo

Haemonetics

NYSE:HAE
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
ICU Medical logo

ICU Medical

NASDAQ:ICUI
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
Merit Medical Systems logo

Merit Medical Systems

NASDAQ:MMSI
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
Inari Medical logo

Inari Medical

NASDAQ:NARI
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Nevro logo

Nevro

NYSE:NVRO
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.